
Cytokinetics, Incorporated CYTK
$ 63.82
0.65%
Quarterly report 2025-Q3
added 11-05-2025
Cytokinetics, Incorporated Interest Expense 2011-2026 | CYTK
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Cytokinetics, Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.7 M | 28.3 M | 19.4 M | 16.4 M | 16 M | 6.62 M | 3.8 M | 3.02 M | 2.7 M | 268 K | - | - | 3 K | 35 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.7 M | 3 K | 11.2 M |
Quarterly Interest Expense Cytokinetics, Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.4 M | 11.1 M | - | 8.93 M | 12.7 M | - | 7.14 M | 7.04 M | 6.96 M | - | 6.8 M | 2.81 M | 2.75 M | - | 4.16 M | 4.07 M | 3.99 M | - | 3.98 M | 3.89 M | 4.08 M | - | 1.34 M | 1.38 M | 1.17 M | - | 867 K | 898 K | 863 K | - | 806 K | 782 K | 745 K | - | 714 K | 707 K | 563 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.7 M | 563 K | 4.02 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Adagene
ADAG
|
1.11 M | $ 2.4 | -3.61 % | $ 135 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.62 | 1.91 % | $ 8.71 B | ||
|
Biogen
BIIB
|
250 M | $ 172.5 | 0.53 % | $ 25.1 B | ||
|
Catalyst Biosciences
CBIO
|
1.04 M | $ 12.1 | -5.47 % | $ 797 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Cellectis S.A.
CLLS
|
371 K | $ 4.16 | -5.88 % | $ 116 M | ||
|
BioXcel Therapeutics
BTAI
|
20.2 M | $ 1.79 | -1.92 % | $ 4.54 M | ||
|
BioLineRx Ltd.
BLRX
|
9.07 M | $ 2.98 | -3.75 % | $ 908 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Ascendis Pharma A/S
ASND
|
65.5 M | $ 231.73 | -1.55 % | $ 5 B | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
5.26 M | $ 67.09 | 0.06 % | $ 8.97 B | ||
|
Compugen Ltd.
CGEN
|
281 K | $ 2.05 | -2.15 % | $ 184 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 4.41 | -1.34 % | $ 9.6 B | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-20.7 M | - | - | $ 1.01 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-807 K | - | -15.15 % | $ 60.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
4.08 M | $ 26.4 | 1.85 % | $ 1.28 B | ||
|
Coherus BioSciences
CHRS
|
40.5 M | $ 2.27 | 10.19 % | $ 214 M | ||
|
Amneal Pharmaceuticals
AMRX
|
11.8 M | $ 13.54 | 1.12 % | $ 4.18 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Athira Pharma
ATHA
|
3.96 M | - | - | $ 269 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 26.48 | 2.16 % | $ 1.71 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.73 | 1.11 % | $ 17.1 M | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B |